精密科學 EXAS 深 滬
等待開盤 10-29 09:30:00 美东时间
104.91
0.000
0.00%
華盛通- 最 高--
- 今 開--
- 成交量 0股
- 最 低 --
- 昨 收 104.91
- 總市值 2003.78万
- 52周最高 104.98
- 市盈率 靜 --
- 換手率 0.00%
- 52周最低 38.8118
- 委 比 0.00%
- 總股本 0.00亿
- 歷史最高 159.54
- 量 比 0
- 振 幅 0.00%
- 歷史最低 4.67
- 每 手 1
- 風險率 13.55%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Abbott launches "SimpleScreen" blood test to expand cancer screening
Abbott Laboratories (ABT) announced on Wednesday that it launched SimpleScreen CRC in the U.S., an FDA-approved blood test to screen for colorectal cancer in adults 45+ at average risk. The test, deve...
09-30 20:35
Humacyte Bolsters Board for Upcoming Commercial Expansion
Humacyte ( ($HUMA) ) has shared an announcement. On September 22, 2026, Humacyt...
09-29 05:14
Humacyte Expands Board Expertise with Appointment of Scott Coward and Paul Kuznik
Humacyte, Inc. has announced the addition of Scott Coward and Paul Kuznik to its Board of Directors. Both bring extensive experience in commercialization, leadership, and global operations. Coward, formerly with Exact Sciences, has expertise in public company governance and legal affairs. Kuznik, a veteran in vascular healthcare, has led commercialization efforts in cardiovascular devices. Their加入 is expected to support Humacyte's ongoing product...
09-28 12:00
Abbott rises as guidance hike tops expectations
Abbott Laboratories (ABT) added ~3% in the premarket on Thursday after the MedTech giant boosted its full-year outlook ahead of Street estimates following a better-than-expected Q2 2026 earnings repor...
07-16 20:39
Abbott gains as Baird issues new Outperform on growth outlook
Shares of Abbott Laboratories (ABT) gained on Wednesday after Baird initiated coverage with an Outperform rating and a $121 price target, citing a stable growth trajectory for the MedTech company driv...
07-01 22:15
雅培(ABT)股票6月25日盘中上涨3.12%：原因全解读
• 雅培与ALZpath合作，共同开发一种基于血液的阿尔茨海默病诊断测试。 • FreeStyle Libre的强劲销售和临床试验数据推动了医疗器械业务的增长。 • 分析师维持看涨评级，理由是该股的分红历史以及近期估值偏低。
06-25 19:16
Nano Dimension and Infinite Epigenetics Provide Additional Information Regarding Proposed Business Combination
Nano Dimension Ltd. and Infinite Epigenetics issued a shareholder update detailing their proposed business combination. The update addresses Murchinson Ltd.'s concerns, emphasizing Infinite's proven science, commercial success, and AI-driven platform. The transaction aims to create long-term value by leveraging Infinite's epigenetic data and diagnostics capabilities, while Nano's capital will support its growth and AI development. The combination...
06-16 23:43
